Author Archives: Megan Thomas

#Covid-19 vaccine #Drug development #Drug discovery #Immunology / Virology & Vaccines #Vaccines

New DDW Highlights podcast out now

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines… Read More

#News

#DDW Highlights podcast

DDW Highlights: 25 September 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  As we approach another autumn/winter season in the northern hemisphere, Covid-19 vaccines… Read More

#Podcasts

#Artificial intelligence (AI) #Benchling #Drug discovery #Lab automation #Proscia #Webinar

The benefits and innovations in AI and lab automation

Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn… Read More

#News

Corporate collaboration
#Cancer #Orano Med #Orbit Discovery #Peptides #Radiopharmaceuticals

Collaboration to discover novel targeted radioligand therapies

Orano Med, a biotechnology company developing Lead-212 (212Pb) targeted alpha therapy against cancer, and Orbit Discovery, a company discovering therapeutic peptide hits, have entered into a collaboration to discover specific peptide receptor radionuclide therapies (PRRT) against cancer cells and advance the development of novel radiopharmaceuticals.   Under… Read More

#Cancer Research #News

Cancer cells
#Bispecific therapeutics #Cancer research #Collaboration #Drug development #Immatics #Moderna #mRNA

Multi-platform collab to develop innovative oncology therapeutics 

Moderna and Immatics have announced a strategic research and development collaboration to pioneer novel and transformative therapies for cancer patients with high, unmet medical need.   This broad multi-platform collaboration will leverage the scientific expertise and core operational capabilities of both companies, combining Immatics’ TCR platform with Moderna’s… Read More

#Cancer Research #News

Bladder cancer
#Bladder cancer #EMA #Janssen #Marketing approval authorisation #Regulatory #Urothelial carcinoma

Janssen submits EMA filing for bladder cancer treatment 

The Janssen Pharmaceutical Companies of Johnson & Johnson has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval of erdafitinib for the treatment of adult patients with locally advanced unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible fibroblast growth factor receptor 3 (FGFR3)… Read More

#Cancer Research #News

Cancer cells
#biological engineering #Bolt Biotherapeutics #Cancer research #Drug delivery #Drug discovery #Immunology

New podcast: In conversation with Shelley Ackerman, Bolt Biotherapeutics

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Shelley… Read More

#News

Cancer cells
#In Conversation Series

Delivering transformative treatments to cancer patients

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Shelley… Read More

#Podcasts

#AstraZeneca #Business #Pfizer #Quarterly review #Regulatory #Sanofi

Drug discovery quarterly review: Second quarter 2023  

As the second quarter of 2023 draws to a close, DDW’s Megan Thomas reviews key updates and results from three top pharmaceutical companies. Business updates   Pfizer reported second quarter 2023 revenues totalling $12.7 billion, a decrease of $15.0 billion, or 54%, compared to the prior year quarter, reflecting an operational… Read More

#Business & Investment #Exclusive Content #Regulatory

Quantum drug discovery
#Artificial intelligence (AI) #Drug design #Drug discovery #Enzymes #Funding #Kuano #Quantum computing

£1.8 million raised to accelerate quantum drug discovery 

Kuano, a drug discovery company combining quantum mechanics with AI to design the next generation of medicines, has raised £1.8M in seed funding, which will facilitate further validation of Kuano’s quantum simulation platform for the design of more effective drug candidates targeting enzymes, as well as continued company growth through… Read More

#Business & Investment #News

Long Covid
#Covid-19 #Immunology #Long Covid #Psychiatry #SARS-CoV-2

New post-Covid study links infection and retrovirus 

A Translational Psychiatry publication indicates that SARS-CoV-2 infection, even when unnoticed or asymptomatic, can have an influence on the activation of the Human Endogenous Retrovirus W (W-ENV) protein in psychotic patients, in a context of innate immune inflammation.   GeNeuro, a biopharmaceutical company developing treatments… Read More

#Covid-19 #News

#Imaging #Revvity

Imaging technologies to drive discoveries 

Revvity has launched an imaging portfolio designed to drive innovation across diverse applications in preclinical research with the launch of three imaging systems.   These systems include the next-generation IVIS Spectrum 2 and the IVIS SpectrumCT 2 imaging systems, as well as the QuantumTM GX3 microCT. Globally,… Read More

#News

GBP pound sterling funding
#BDD Clinical Trials #Clinical trials #Funding

£2 million secured to fuel expansion in early phase clinical trials  

Integrated drug formulation and clinical trials company, BDD Clinical Trials, has secured a further round of investment for £2M to aid the company’s expansion in response to growing demand for both its patented drug delivery technology and specialist clinical trial services.  The latest investment package follows a strong 18 months… Read More

#Business & Investment #News

Future lab, AI and digital data
#Artificial intelligence (AI) #Benchling #Drug discovery #Lab automation #Proscia #Webinar

Webinar: Key benefits and latest innovations in AI and lab automation

Hosted by DDW and co-sponsored by Benchling and Proscia, “AI and Lab Automation: What are the key benefits and latest innovations?” will be free to attend on 10 October at 7AM PDT / 10AM EST / 3PM BST / 4PM CET. Join this free webinar to learn… Read More

#News

Lungs
#Ariceum Therapeutics #Lung cancer #Murdoch University Health Center #Radiopharmaceuticals #Small cell lung cancer #Theranostics

First patient dosed in Phase Ib study in small cell lung cancer 

Ariceum Therapeutics, a biotech company developing radiopharmaceutical products for the diagnosis and treatment of certain hard-to-treat cancers, has dosed the first patient with its first-in-class lead molecule, satoreotide, targeting extensive stage small cell lung cancer (ES-SCLC), at the Murdoch University Health Center in Perth, Australia.  Ariceum has… Read More

#News

#Collaboration #Drug development #Drug discovery #Horizon Europe #Mergers and acquisitions #Partnership

New: DDW Highlights 11 September 2023

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  This week we have seen the vital importance of collaboration to the… Read More

#News